The second phase of the clinical study aims to find out how effective and safe these products are. Up to three hundred patients treated with SOT101 in combination with a standard dose of KEYTRUDA should be enrolled in the study. These should include patients in the United States and selected European countries with six different diagnoses, non-small cell lung cancer, squamous cell carcinoma, colorectal cancer, second-line hepatocellular carcinoma, metastatic castration-resistant prostate cancer, and patients with ovarian cancer.
Hope for a cure for cancer
At the beginning of December, the biotechnology company SOTIO Biotech received CZK 7.1 billion from the PPF Group, of which it is a part, for the further development of new methods of cancer treatment, especially SOT101.
This potential cancer drug works by stimulating the immune system, thereby activating white blood cells, especially T-lymphocytes and NK cells, to kill tumor cells. In immunooncology, it is a promising therapeutic substance, which also combines well with established oncological drugs. The drug is currently being tested as monotherapy in patients with skin and kidney tumors.
Medicine batteries
By the end of 2023, three new products being developed by SOTIO will also enter the clinical trials phase. BOXR1030 is the company’s flagship project on CAR-T cell therapies for solid tissue tumors. The drug is prepared for each patient separately using his own immune system. Laboratory-treated white blood cells (T-cells) are injected back into the patient’s body, where they find the tumor cells and kill them. The clinical study is already approved and will begin in early 2022.
–
SOT102 is an anti-tumor medicine on the ADC (antibody-drug conjugate) platform. ADCs are carriers of cytostatics (such as chemotherapy) with the ability to selectively select a tumor cell, attach to its surface, and release a highly effective drug after penetrating it without damaging healthy cells. The first clinical study in patients with gastric and pancreatic tumors is scheduled to begin in March 2022.
By the end of 2022, SOTIO also plans to launch a clinical trial with SOT201. It is a substance that combines SOT101 and a PD-1 inhibitor in a fixed combination.
– .
